

# Phosphorus - Inorganic

(4 x 25 ml) 100 test REF: 294 001 REF: 294 002 (2 x 100 ml) 200 test (4 x 100 ml) 400 test

#### Intended Use

Spectrum Diagnostics phosphorus reagent is intended for the invitro quantitative, diagnostic determination of phosphorus in human serum, plasma or urine on both automated and manual systems.

#### Background

The body of human adult contains approximately 620 g of phosphorus entirely in the form of phosphates distributed fairly equally between extracellular and intracellular compartments. About 85 % of extracellular phosphate occurs in inorganic forms as hydroxyapatite. In plasma or serum, most phosphate exist in the inorganic form (Pi); this fraction is present as the mono-and dihydrogen forms, the relative proportions varying with the pH. Intracellularly, phosphate occurs mainly as phospholipids and phosphoproteins; this fraction is termed organic phosphate. Increased serum phosphate levels may occur in renal failure, hypervitaminosis D and hypoparathyroidism. Reduced serum phosphate levels are seen in vitamin D deficiency, rickets, hyperparathyroidism and Fanconi's syndrome.

#### Method

UV - phosphomolybdate method.

#### Assay principle

Inorganic phosphate reacts with ammonium molybdate in presence of sulfuric acid to form non-reduced phosphomolybdate.

Phosphate + Ammonium molybdate H<sub>2</sub>SO<sub>4</sub> Nonreduced phosphomolybdate

The concentration of phoshomolybdate formed is directly proportional to the inorganic phosphate concentration. It is determined by measuring the increase in absorbance at 340 nm.

#### Reagents

Standard phosphorus (St)

1 61 mmol/l 5 mg/dl Reagent (R) Ammonium molybdate 3.5 mmol/L Sulphuric acid 750 mmol/L Surfactants

(C)-Corrosive contains caustic materials.

Causes severe burns.

**R41** Risk of serious damage to eyes. S26

In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

After contact with skin, wash immediately with plenty of

For further information, refer to the Phosphorus, Inorganic reagent material safety data sheet.

## **Precautions and Warnings**

Do not ingest or inhalate. In case of contact with eyes or skin; rinse immediately with plenty of soap and water. In case of severe injuries; seek medical advice immediately.

### Reagent Storage and Stability

Reagents are supplied ready-to-use and stable until expiration date stated on label when stored refrigerated at 2 - 8 OC.Once opened, the reagent and standard are stable for 3 months at the specified temperature.

## Deterioration

If absorbance of reagent measured at 340 nm against distilled water as reference is greater than 0.5, it should be discarded.

#### SYMBOLS IN PRODUCT LABELLING



### **Specimen Collection and Preservation**

Serum or plasma

Serum specimens collected from fasting patients are the preferable specimens since meals lower inorganic phosphate level. The heparin is the only acceptable anticoagulant. EDTA, fluoride and citrate lower the inorganic phosphate level. Serum and plasma should be separated from erythrocytes as soon as possible to avoid the leakage of inorganic phosphate and phosphate esters into the plasma media. The biological half-life in serum is few minutes.

Stability: 1 day at 15 – 25 °C; 4 days at 4 – 8 °C; 1 year at -20 °C

Urine

Urine specimens should be collected in an acid-washed, detergent-

#### **System Parameters**

Wavelength 340 nm Optical path Assay type **End-point** Direction Sample : Reagent Ratio Increase 1:100 e.g.: Reagent volume 1 ml Sample volume 10 μΙ

15 - 25 °C or 37 °C Temperature Reagent blank 10 minutes at 15 – 25 °C or 5 minutes at 37 °C Zero adjustment Incubation time

Reagent Blank Limits Low 0.00 AU High 0.5 AU

Sensitivity 1 mg/dL Linearity 20 mg/dL (6.4 mmol/L)

## **Procedure**

	Blank	Standard	Sample	
Reagent	1 ml	1 ml	1 ml	
Distilled water	10 μΙ			
Standard		10 μΙ		
Sample			10 μΙ	

Mix, wait for 10 minutes at 15-25 °C or 5 minutes at 37 °C, then measure absorbance of specimen (Aspecimen) and standard (<sup>A</sup>standard) against reagent blank within 30 minutés.

#### Calculation

Aspecimen Serum phosphorus conc. (mg/dl) = x 5 A<sub>standard</sub> A<sub>specimen</sub> Urine phosphorus conc. (mg/dl) = x 5 x 10 A<sub>standard</sub>

For turbid highly icteric sera , prepare a seum blank by adding 10  $\mu l$  serum to 1 ml saline into a labeled test tube. Read absorbance of serum blank at 340 nm vs water and subtract from test absorbance before calculating results.

## **Quality Control**

Normal and abnormal commercial control serum of known concentrations should be analyzed with each run.

#### **Performance Characteristics**

#### **Precision**

Within run (Repeatability)

	Level 1	Level 2
n	20	20
Mean (mg/dL)	5.49	8.92
SD	0.19	0.128
CV%	3.39	1.46

#### Run to run (Reproducibility)

	Level 1	Level 2
n	20	20
Mean (mg/dL)	5.61	9.1
SD	0.29	0.133
CV%	3.97	1.5

## **Methods Comparison**

A comparison between Spectrum Diagnostics Phosphorus reagent and a commercial reagent of the same methodology was performed on 20 human sera. A correlation of 0.974 was obtained.

#### Sensitivity

When run as recommended, the minimum detection limit of this assay is 1 mg/dL.

#### Linearity

The reaction is linear up to phosphorus concentration of 20 mg/dL. Specimens showing higher concentration should be diluted 1+4 using physiological saline and repeat the assay (result  $\times$  5).

## Interfering Substances

#### Haemolysis

Avoid haemolysis since RBCs contain very high levels of inorganic phosphate.

#### **Icterus**

No significant interference up to a bilirubin level of 30 mg/dL.

#### Lipemia

No significant interference.

#### **Anticoagulants**

EDTA, citrate and fluoride interfere with the test.

## **Expected Values**

Serum (fasting)

(0.87 - 1.45 mmol/L)2.7 - 4.5 mg/dLAdults . 2.7 - 4.3 mg/dL (0.67 - 1.45 mmol/L) : 4.5 - 5.5 mg/dL (1.45 - 1.78 mmol/L) : 4.5 - 6.7 mg/dL (1.45 - 2.16 mmol/L) : 5.0 - 9.6 mg/dL (1.60 - 3.10 mmol/L) : 0.3 - 1.0 g/24 hrs (11 - 32 mmol / day) Children < 12 years Children < 1 year Neonates Urine (24 hrs)

Spectrum Diagnostics does not interpret the results of a clinical laboratory procedure; interpretition of the results is considered the responsibilaty of qualified medical personnel. All indications of clinical significance are supported by literature references.

## **Analytical Range**

1 - 20 mg/dL

#### **Waste Disposal**

This product is made to be used in professional laboratories. Please consult local regulations for a correct waste disposal.

\$56: dispose of this material and its container at hazardous or special waste collection point.

\$57: use appropriate container to avoid environmental contamination. \$61: avoid release in environment. refer to special instructions/safety data sheets.

#### References

- 1. Daly JA, Ertingshausen G: Direct method for determination of inorganic phosphate in serum with the centerifichem. Clin Chem 18:263, 1972.
- 2. Frankel S:Electrolytes. In: Gradwhol's clinical laboratory methods and diagnosis, 6 th ed. S Frankel, S Reitman, Editors, Mosby, St. Iouis (MO), 1963, p 188,1963.

  3. Hanok A, Kao J: The stability of a reconstituted serum for the
- assay of fifteen chemical constituents. Clin Chem 14:58, 1968.
- Young DS: Effects of drugs on clinical laboratory tests. 3 ed ed., AACC press, Washington (DC), 1990; Supplement No.1,1991.

ORDERING INFORMATION				
CATALOG NO.	QUANTITY			
294 001 294 002 294 003	4 x 25 ml 2 x 100 ml 4 x 100 ml			

Egyptian Company for Biotechnology (S.A.E)

Obour city industrial area. block 20008 pièce 19 A. Cairo. Egypt. Tel: +202 4489 2248 Fax: +202 4489 2247 www.spectrum-diagnostics.com E-mail:info@spectrum-diagnostics.com







